APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oral Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032

Report ID 174019790128 December 2025114 pages

Choose your research edition.

Industry ResearchOral Factor Xa Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Oral Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Factor Xa Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral Factor Xa Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Factor Xa Inhibitors include Accord Healthcare, Apotex, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Lupin, Mylan and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oral Factor Xa Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oral Factor Xa Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oral Factor Xa Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oral Factor Xa Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Oral Factor Xa Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oral Factor Xa Inhibitors Market by Company

Accord Healthcare

Apotex

Bayer

Bristol Myers Squibb

Daiichi Sankyo

Janssen Pharmaceuticals

Lupin

Mylan

Pfizer

Zydus

HEC Pharma

Hansoh Pharma

Huahai Pharmaceutical

Shanghai Huilun Pharmaceutical

Qilu Pharmaceutical

Cspc Ouyi Pharmaceutical

Yangtze River Pharmaceutical

Zhejiang Hisun Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Oral Factor Xa Inhibitors Segment by Type

Edoxaban

Rivaroxaban

Apixaban

Oral Factor Xa Inhibitors Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Oral Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Factor Xa Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Oral Factor Xa Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Edoxaban Table 2. Major Company of Rivaroxaban Table 3. Major Company of Apixaban Table 4. Global Oral Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 6. Global Oral Factor Xa Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 7. Global Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 8. Global Oral Factor Xa Inhibitors Sales Market Share in Value by Type (2021-2026) Table 9. Global Oral Factor Xa Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 10. Global Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 11. Global Oral Factor Xa Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 12. Global Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 13. Global Oral Factor Xa Inhibitors Sales Market Share in Value by Type (2027-2032) Table 14. Global Oral Factor Xa Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 15. North America Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 16. North America Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 18. Europe Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 22. Latin America Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 25. Oral Factor Xa Inhibitors Industry Trends Table 26. Oral Factor Xa Inhibitors Industry Drivers Table 27. Oral Factor Xa Inhibitors Industry Opportunities and Challenges Table 28. Oral Factor Xa Inhibitors Industry Restraints Table 29. Global Oral Factor Xa Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Oral Factor Xa Inhibitors Revenue Market Share by Company (2021-2026) Table 31. Global Oral Factor Xa Inhibitors Sales by Company (2021-2026) & (K Units) Table 32. Global Oral Factor Xa Inhibitors Sales Share by Company (2021-2026) Table 33. Global Oral Factor Xa Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Oral Factor Xa Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Oral Factor Xa Inhibitors Major Company Production Sites and Headquarters Table 36. Global Oral Factor Xa Inhibitors Company, Product Type & Application Table 37. Global Oral Factor Xa Inhibitors Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Oral Factor Xa Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Oral Factor Xa Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 42. Global Oral Factor Xa Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 43. Global Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 44. Global Oral Factor Xa Inhibitors Sales Market Share in Value by Region (2021-2026) Table 45. Global Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Oral Factor Xa Inhibitors Sales by Region (2027-2032) & (K Units) Table 47. Global Oral Factor Xa Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 48. Global Oral Factor Xa Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 49. Global Oral Factor Xa Inhibitors Sales Market Share in Value by Region (2027-2032) Table 50. Global Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Oral Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 53. Global Oral Factor Xa Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 54. Global Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 55. Global Oral Factor Xa Inhibitors Sales Market Share in Value by Application (2021-2026) Table 56. Global Oral Factor Xa Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 57. Global Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 58. Global Oral Factor Xa Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 59. Global Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 60. Global Oral Factor Xa Inhibitors Sales Market Share in Value by Application (2027-2032) Table 61. Global Oral Factor Xa Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 62. North America Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 63. North America Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 65. Europe Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 69. Latin America Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 72. Accord Healthcare Company Information Table 73. Accord Healthcare Business Overview Table 74. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio Table 76. Accord Healthcare Recent Development Table 77. Apotex Company Information Table 78. Apotex Business Overview Table 79. Apotex Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Apotex Oral Factor Xa Inhibitors Product Portfolio Table 81. Apotex Recent Development Table 82. Bayer Company Information Table 83. Bayer Business Overview Table 84. Bayer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bayer Oral Factor Xa Inhibitors Product Portfolio Table 86. Bayer Recent Development Table 87. Bristol Myers Squibb Company Information Table 88. Bristol Myers Squibb Business Overview Table 89. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio Table 91. Bristol Myers Squibb Recent Development Table 92. Daiichi Sankyo Company Information Table 93. Daiichi Sankyo Business Overview Table 94. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio Table 96. Daiichi Sankyo Recent Development Table 97. Janssen Pharmaceuticals Company Information Table 98. Janssen Pharmaceuticals Business Overview Table 99. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio Table 101. Janssen Pharmaceuticals Recent Development Table 102. Lupin Company Information Table 103. Lupin Business Overview Table 104. Lupin Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Lupin Oral Factor Xa Inhibitors Product Portfolio Table 106. Lupin Recent Development Table 107. Mylan Company Information Table 108. Mylan Business Overview Table 109. Mylan Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Mylan Oral Factor Xa Inhibitors Product Portfolio Table 111. Mylan Recent Development Table 112. Pfizer Company Information Table 113. Pfizer Business Overview Table 114. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Pfizer Oral Factor Xa Inhibitors Product Portfolio Table 116. Pfizer Recent Development Table 117. Zydus Company Information Table 118. Zydus Business Overview Table 119. Zydus Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Zydus Oral Factor Xa Inhibitors Product Portfolio Table 121. Zydus Recent Development Table 122. HEC Pharma Company Information Table 123. HEC Pharma Business Overview Table 124. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. HEC Pharma Oral Factor Xa Inhibitors Product Portfolio Table 126. HEC Pharma Recent Development Table 127. Hansoh Pharma Company Information Table 128. Hansoh Pharma Business Overview Table 129. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio Table 131. Hansoh Pharma Recent Development Table 132. Huahai Pharmaceutical Company Information Table 133. Huahai Pharmaceutical Business Overview Table 134. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 136. Huahai Pharmaceutical Recent Development Table 137. Shanghai Huilun Pharmaceutical Company Information Table 138. Shanghai Huilun Pharmaceutical Business Overview Table 139. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 141. Shanghai Huilun Pharmaceutical Recent Development Table 142. Qilu Pharmaceutical Company Information Table 143. Qilu Pharmaceutical Business Overview Table 144. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 146. Qilu Pharmaceutical Recent Development Table 147. Cspc Ouyi Pharmaceutical Company Information Table 148. Cspc Ouyi Pharmaceutical Business Overview Table 149. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 151. Cspc Ouyi Pharmaceutical Recent Development Table 152. Yangtze River Pharmaceutical Company Information Table 153. Yangtze River Pharmaceutical Business Overview Table 154. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 156. Yangtze River Pharmaceutical Recent Development Table 157. Zhejiang Hisun Pharmaceutical Company Information Table 158. Zhejiang Hisun Pharmaceutical Business Overview Table 159. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 161. Zhejiang Hisun Pharmaceutical Recent Development Table 162. Chia Tai Tianqing Pharmaceutical Company Information Table 163. Chia Tai Tianqing Pharmaceutical Business Overview Table 164. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 166. Chia Tai Tianqing Pharmaceutical Recent Development Table 167. North America Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 168. North America Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 169. North America Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 170. North America Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 171. North America Oral Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 172. North America Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. North America Oral Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 174. North America Oral Factor Xa Inhibitors Market Share by Country (2021-2026) Table 175. North America Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. North America Oral Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 177. Europe Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 178. Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 179. Europe Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 180. Europe Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 181. Europe Oral Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 182. Europe Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Europe Oral Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 184. Europe Oral Factor Xa Inhibitors Market Share by Country (2021-2026) Table 185. Europe Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Europe Oral Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 187. Asia-Pacific Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 188. Asia-Pacific Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 189. Asia-Pacific Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 190. Asia-Pacific Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 191. Asia-Pacific Oral Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 192. Asia-Pacific Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 193. Asia-Pacific Oral Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 194. Asia-Pacific Oral Factor Xa Inhibitors Market Share by Country (2021-2026) Table 195. Asia-Pacific Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 196. Asia-Pacific Oral Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 197. Latin America Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 198. Latin America Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 199. Latin America Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 200. Latin America Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 201. Latin America Oral Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 202. Latin America Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 203. Latin America Oral Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 204. Latin America Oral Factor Xa Inhibitors Market Share by Country (2021-2026) Table 205. Latin America Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 206. Latin America Oral Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 207. Middle East and Africa Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 208. Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 209. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 210. Middle East and Africa Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 211. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 212. Middle East and Africa Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 213. Middle East and Africa Oral Factor Xa Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 214. Middle East and Africa Oral Factor Xa Inhibitors Market Share by Country (2021-2026) Table 215. Middle East and Africa Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 216. Middle East and Africa Oral Factor Xa Inhibitors Market Share Forecast by Country (2027-2032) Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. Oral Factor Xa Inhibitors Distributors List Table 220. Oral Factor Xa Inhibitors Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. Oral Factor Xa Inhibitors Image Figure 2. Global Oral Factor Xa Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Factor Xa Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 5. Edoxaban Image Figure 6. Global Edoxaban Sales YoY Growth (2021-2032) & (K Units) Figure 7. Rivaroxaban Image Figure 8. Global Rivaroxaban Sales YoY Growth (2021-2032) & (K Units) Figure 9. Apixaban Image Figure 10. Global Apixaban Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Oral Factor Xa Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Oral Factor Xa Inhibitors Market Share by Type 2025 VS 2032 Figure 13. North America Oral Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 14. North America Oral Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 15. Europe Oral Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. Europe Oral Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Oral Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Oral Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Latin America Oral Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Oral Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Oral Factor Xa Inhibitors Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Pulmonary Embolism Image Figure 26. Global Pulmonary Embolism Sales YoY Growth (2021-2032) & (K Units) Figure 27. Deep Vein Thrombosis Image Figure 28. Global Deep Vein Thrombosis Sales YoY Growth (2021-2032) & (K Units) Figure 29. Atrial Fibrillation Image Figure 30. Global Atrial Fibrillation Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Oral Factor Xa Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Oral Factor Xa Inhibitors Market Share by Application 2025 VS 2032 Figure 35. North America Oral Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 36. North America Oral Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 37. Europe Oral Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. Europe Oral Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Oral Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Oral Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Latin America Oral Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Oral Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share in Value by Application in 2025 Figure 45. North America Oral Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Oral Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Oral Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Oral Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Oral Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Oral Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Oral Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Oral Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Oral Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Oral Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Oral Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Oral Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Oral Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Oral Factor Xa Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Oral Factor Xa Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Oral Factor Xa Inhibitors Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Oral Factor Xa Inhibitors Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Edoxaban
  • Rivaroxaban
  • Apixaban
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Bayer
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • Janssen Pharmaceuticals
  • Lupin
  • Mylan
  • Pfizer
  • Zydus
  • HEC Pharma
  • Hansoh Pharma
  • Huahai Pharmaceutical
  • Shanghai Huilun Pharmaceutical
  • Qilu Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Yangtze River Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Factor Xa Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Oral Factor Xa Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Oral Factor Xa Inhibitors Market by Type
  6. 1.3.1 Edoxaban
  7. 1.3.2 Rivaroxaban
  8. 1.3.3 Apixaban
  9. 1.4 Global Oral Factor Xa Inhibitors Market Size by Type
  10. 1.4.1 Global Oral Factor Xa Inhibitors Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Oral Factor Xa Inhibitors Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Oral Factor Xa Inhibitors Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Oral Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Oral Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Oral Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Oral Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Oral Factor Xa Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Oral Factor Xa Inhibitors Industry Trends
  2. 2.2 Oral Factor Xa Inhibitors Industry Drivers
  3. 2.3 Oral Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 2.4 Oral Factor Xa Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Oral Factor Xa Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by Oral Factor Xa Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by Oral Factor Xa Inhibitors Price (2021-2026)
  4. 3.4 Global Oral Factor Xa Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Factor Xa Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global Oral Factor Xa Inhibitors Company, Product Type & Application
  7. 3.7 Global Oral Factor Xa Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Factor Xa Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Factor Xa Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3
4 Oral Factor Xa Inhibitors Regional Status and Outlook
  1. 4.1 Global Oral Factor Xa Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Oral Factor Xa Inhibitors Historic Market Size by Region
  3. 4.2.1 Global Oral Factor Xa Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Oral Factor Xa Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Oral Factor Xa Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Oral Factor Xa Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global Oral Factor Xa Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Oral Factor Xa Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Oral Factor Xa Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Oral Factor Xa Inhibitors by Application
  1. 5.1 Oral Factor Xa Inhibitors Market by Application
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global Oral Factor Xa Inhibitors Market Size by Application
  7. 5.2.1 Global Oral Factor Xa Inhibitors Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Oral Factor Xa Inhibitors Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Oral Factor Xa Inhibitors Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Oral Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Oral Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Oral Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Oral Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Oral Factor Xa Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Accord Healthcare
  2. 6.1.1 Accord Healthcare Company Information
  3. 6.1.2 Accord Healthcare Business Overview
  4. 6.1.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio
  6. 6.1.5 Accord Healthcare Recent Developments
  7. 6.2 Apotex
  8. 6.2.1 Apotex Company Information
  9. 6.2.2 Apotex Business Overview
  10. 6.2.3 Apotex Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Apotex Oral Factor Xa Inhibitors Product Portfolio
  12. 6.2.5 Apotex Recent Developments
  13. 6.3 Bayer
  14. 6.3.1 Bayer Company Information
  15. 6.3.2 Bayer Business Overview
  16. 6.3.3 Bayer Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bayer Oral Factor Xa Inhibitors Product Portfolio
  18. 6.3.5 Bayer Recent Developments
  19. 6.4 Bristol Myers Squibb
  20. 6.4.1 Bristol Myers Squibb Company Information
  21. 6.4.2 Bristol Myers Squibb Business Overview
  22. 6.4.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio
  24. 6.4.5 Bristol Myers Squibb Recent Developments
  25. 6.5 Daiichi Sankyo
  26. 6.5.1 Daiichi Sankyo Company Information
  27. 6.5.2 Daiichi Sankyo Business Overview
  28. 6.5.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio
  30. 6.5.5 Daiichi Sankyo Recent Developments
  31. 6.6 Janssen Pharmaceuticals
  32. 6.6.1 Janssen Pharmaceuticals Company Information
  33. 6.6.2 Janssen Pharmaceuticals Business Overview
  34. 6.6.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio
  36. 6.6.5 Janssen Pharmaceuticals Recent Developments
  37. 6.7 Lupin
  38. 6.7.1 Lupin Company Information
  39. 6.7.2 Lupin Business Overview
  40. 6.7.3 Lupin Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Lupin Oral Factor Xa Inhibitors Product Portfolio
  42. 6.7.5 Lupin Recent Developments
  43. 6.8 Mylan
  44. 6.8.1 Mylan Company Information
  45. 6.8.2 Mylan Business Overview
  46. 6.8.3 Mylan Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Mylan Oral Factor Xa Inhibitors Product Portfolio
  48. 6.8.5 Mylan Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Oral Factor Xa Inhibitors Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Zydus
  56. 6.10.1 Zydus Company Information
  57. 6.10.2 Zydus Business Overview
  58. 6.10.3 Zydus Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Zydus Oral Factor Xa Inhibitors Product Portfolio
  60. 6.10.5 Zydus Recent Developments
  61. 6.11 HEC Pharma
  62. 6.11.1 HEC Pharma Company Information
  63. 6.11.2 HEC Pharma Business Overview
  64. 6.11.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 HEC Pharma Oral Factor Xa Inhibitors Product Portfolio
  66. 6.11.5 HEC Pharma Recent Developments
  67. 6.12 Hansoh Pharma
  68. 6.12.1 Hansoh Pharma Company Information
  69. 6.12.2 Hansoh Pharma Business Overview
  70. 6.12.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio
  72. 6.12.5 Hansoh Pharma Recent Developments
  73. 6.13 Huahai Pharmaceutical
  74. 6.13.1 Huahai Pharmaceutical Company Information
  75. 6.13.2 Huahai Pharmaceutical Business Overview
  76. 6.13.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  78. 6.13.5 Huahai Pharmaceutical Recent Developments
  79. 6.14 Shanghai Huilun Pharmaceutical
  80. 6.14.1 Shanghai Huilun Pharmaceutical Company Information
  81. 6.14.2 Shanghai Huilun Pharmaceutical Business Overview
  82. 6.14.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  84. 6.14.5 Shanghai Huilun Pharmaceutical Recent Developments
  85. 6.15 Qilu Pharmaceutical
  86. 6.15.1 Qilu Pharmaceutical Company Information
  87. 6.15.2 Qilu Pharmaceutical Business Overview
  88. 6.15.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  90. 6.15.5 Qilu Pharmaceutical Recent Developments
  91. 6.16 Cspc Ouyi Pharmaceutical
  92. 6.16.1 Cspc Ouyi Pharmaceutical Company Information
  93. 6.16.2 Cspc Ouyi Pharmaceutical Business Overview
  94. 6.16.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  96. 6.16.5 Cspc Ouyi Pharmaceutical Recent Developments
  97. 6.17 Yangtze River Pharmaceutical
  98. 6.17.1 Yangtze River Pharmaceutical Company Information
  99. 6.17.2 Yangtze River Pharmaceutical Business Overview
  100. 6.17.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  102. 6.17.5 Yangtze River Pharmaceutical Recent Developments
  103. 6.18 Zhejiang Hisun Pharmaceutical
  104. 6.18.1 Zhejiang Hisun Pharmaceutical Company Information
  105. 6.18.2 Zhejiang Hisun Pharmaceutical Business Overview
  106. 6.18.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  108. 6.18.5 Zhejiang Hisun Pharmaceutical Recent Developments
  109. 6.19 Chia Tai Tianqing Pharmaceutical
  110. 6.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 6.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 6.19.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  114. 6.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Oral Factor Xa Inhibitors Sales by Country
  2. 7.1.1 North America Oral Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Oral Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America Oral Factor Xa Inhibitors Market Size by Country
  6. 7.2.1 North America Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Oral Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Oral Factor Xa Inhibitors Sales by Country
  2. 8.1.1 Europe Oral Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Oral Factor Xa Inhibitors Market Size by Country
  6. 8.2.1 Europe Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Oral Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Oral Factor Xa Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific Oral Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Oral Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Oral Factor Xa Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Oral Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Oral Factor Xa Inhibitors Sales by Country
  2. 10.1.1 South America Oral Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Oral Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America Oral Factor Xa Inhibitors Market Size by Country
  6. 10.2.1 South America Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Oral Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Oral Factor Xa Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa Oral Factor Xa Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Oral Factor Xa Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa Oral Factor Xa Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Oral Factor Xa Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Oral Factor Xa Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Oral Factor Xa Inhibitors Value Chain Analysis
  2. 12.1.1 Oral Factor Xa Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Oral Factor Xa Inhibitors Production Mode & Process
  7. 12.2 Oral Factor Xa Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Oral Factor Xa Inhibitors Distributors
  10. 12.2.3 Oral Factor Xa Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst